<DOC>
	<DOCNO>NCT01926171</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy icotinib combination whole brain radiotherapy NSCLC patient brain metastasis . The primary endpoint objective response rate intracranial lesion .</brief_summary>
	<brief_title>Icotinib With Whole Brain Radiation Therapy NSCLC Patients With Brain Metastases</brief_title>
	<detailed_description>Non-small cell lung cancer ( NSCLC ) one malignant tumor high incidence brain metastasis . Patients multiple brain metastasis show poor prognosis display untreated median survival 3-6 month , patient die due progression brain metastasis . This study design evaluate safety efficacy icotinib combine whole brain radiotherapy NSCLC patient brain metastasis . The primary endpoint intracranial objective response rate .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological confirmation nonsmallcell lung cancer ( NSCLC ) . Diagnosis nonsystematic brain metastasis Gadoliniumenhanced MRI . More 2 site intracranial metastasis , long diameter intracranial lesion 3cm . No metastasis except brain metastasis . Previous usage EGFRTKI antibody EGFR : gefitinib , erlotinib , herceptin , erbitux . CSF MRI finding consistent metastasis spinal cord , meninges meningeal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>